The molecular biology of von Willebrand disease by Ginsburg, David W.
The molecular biology of von Willebrand disease
D. GINSBURG
Departments of Internal Medicine and Human Genetics and Howard Hughes Medical Institute, University of Michigan Medical
School, Ann Arbor, MI, USA
The ®rst direct evidence of a molecular distinction between
haemophilia A and von Willebrand disease (vWD) came
from the recognition of the dierence in inheritance
pattern, X-linked in the case of haemophilia and autosomal
dominant or recessive for vWD. It is interesting to note that
though von Willebrand did distinguish vWD from haemo-
philia, he incorrectly concluded that vWD is inherited in an
X-linked dominant pattern [1]. It was not until the elegant,
landmark experiments of Nilsson and coworkers in 1957
that haemophilia and vWD were de®nitively established as
due to de®ciencies of distinct proteins [2].
von Willebrand factor (vWF) plays a central role in the
critical initial phases of haemostasis [3±6]. The early
confusion about the relationship between factor VIII (FVIII)
and vWF stemmed from the fact that these two proteins are
associated in plasma as a tight complex, with a stoichio-
metry of & 50±100 : 1 (vWF monomer:FVIII monomer).
The primary haemostatic functions of vWF are the
formation of an adhesive link between the platelet and the
vessel wall at sites of vascular injury and the localization of
FVIII to these sites for subsequent participation in the
coagulation cascade leading to ®brin clot deposition (Fig. 1).
vWF is produced within the endothelial cell and the
megakaryocyte precursor of blood platelets (reviewed in
[7]), giving rise to distinct pools of platelet, plasma, and
subendothelial vWF. vWF is ®rst synthesized as a single
chain 300 kDa precursor protein, which subsequently
dimerizes and multimerizes to form high molecular weight
multimers that are then secreted into plasma via both
constitutive and regulated pathways. vWF in the regulated
pathway is stored in specialized granules within the
endothelial cell termed Weibel±Palade bodies and is
secreted in response to a variety of stimuli, including
treatment with DDAVP.
The complexity of vWD
The bewildering complexity of the vWD clinical spec-
trum, with more than 20 subtypes described, has been
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Summary. von Willebrand disease is the most common
inherited bleeding disorder in humans, with the general
population prevalence estimated to be as high as 1% in
some studies. This condition exhibits extensive hetero-
geneity with over 20 distinct subtypes distinguished based
on subtle clinical and laboratory differences in presenta-
tion. Recent research laboratory advances have shed
considerable new light on the molecular basis of this
disorder. Specific mutations within the von Willebrand
factor gene have been identified in many of the qualitative
variants of von Willebrand disease, providing important
new insight into the structure and function of this central
clotting protein. However, the complex genetic factors
determining the clinical severity of type 1 von Willebrand
disease, the most common variant, still remain largely
unknown and are the subject of current investigation.
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Fig. 1. Function of vWF. vWF is synthesized in endothelial cells and
megakaryocytes, accounting for the free plasma and platelet a-
granule pools, respectively. vWF provides an adhesive link between
platelets and the vessel wall at sites of vascular injury and serves as a
carrier for FVIII in plasma (from [4], with permission).
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made considerably more clear by recent advances in
molecular genetics [4]. The newly revised classi®cation for
vWD [8] recognizes two broad categories associated with
either quantitative (type 1 and type 3) or qualitative (type
2) de®ciency of vWF.
The current classi®cation scheme and the known genetic
defects responsible for these variants are summarized in
Table 1. In type 3, or severe vWD, very low or
undetectable vWF levels are associated with severe and
often life-threatening bleeding, as in the proband of the
original family from the AÊ land Islands. Type 1 vWD is the
most common variant with a mild to moderate quantita-
tive decrease in vWF. The most common type 2 variants,
type 2 A and 2 B, are associated with loss of the largest and
most haemostatically active vWF multimers. Type 2 N
vWD is due to speci®c defects within the FVIII binding
domain of vWF. Finally, the type 2 M classi®cation is
reserved for the remaining miscellaneous variants that do
not ®t well into any of the other categories.
The vWF gene
The critical advance opening the door to a molecular
analysis of vWD was the cloning of the vWF cDNA in
1985 by four independent groups [9±12]. The structure of
the vWF protein deduced from the cDNA, and con®rmed
by direct amino acid sequence analysis [13], is shown
schematically in Fig. 2. This summarizes a considerable
body of work from multiple laboratories localizing
speci®c functional domains within vWF [6]. The structure
of the large and complex vWF gene, as well as
identi®cation of a highly conserved partial pseudogene,
was reported in 1991 by Sadler and coworkers [14]. The
vWF gene spans 178 kb on the short arm of chromosome
12 and is composed of 52 exons. The characterization of
full-length vWF cDNA [9] identi®ed a large propeptide
which was shown to be identical to a previously known
vWF-associated protein termed VW antigen 2 [15]. As
shown in Fig. 2, the FVIII binding domain within vWF has
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Table 1. Classification of von Willebrand disease subtypes*
Subtype Frequency Clinical features Diagnosis Molecular basis
Type 3 1±5: 106 Severe bleeding disorder: Markedly decreased or vWF gene deletions, nonsense, misssense
autosomal recessive inheritance undetectable vWF:Ag, and frameshift mutations throughout
vWF activity and VIII:C gene; other cis-defects in mRNA
expression
Type 1 1±30: 1000; Mild to moderate bleeding; vWF:Ag, vWF activity, A few missense mutations reported,
most common autosomal dominant; and VIII:C all presumed to disrupt function; some cases
vWD variant incomplete penetrance proportionately decreased represent heterozygous form of type 3
(470% of vWD) (approximately 60%) (20±50%). Normal
multimer distribution
Type 2A Approximately Mild to moderate bleeding Variably decresed vWF:Ag, Missense mutations clustered within
10±15% of disorder; generally autosomal vWF activity, and VIII:C; vWF A2 repeat. Two subgroups:
clinical cases dominant through some absent high and group 1 ± defect in intracellular
autosomal recessive, more intermediate size vWF transport; group 2 ± increased
complete penetrance than multimers with prominent proteolysis in plasma after secretion
type 1; generally poor response satellite bands
to DDAVP
Type 2B Uncommon Mild to moderate bleeding Variably decreased vWF Missense mutations clustered in vWF
variant (55% disorder; autosomal dominant, antigen vWF antigen and A1 repeat result in increased or
of clinical vWD) more complete penetrance than VIII:C; loss of large spontaneous binding to platelet
type 1; ? DDAVP multimers; enhanced RIPA;
contraindicated GP1b thrombocytopenia
Type 2M Rare Variable bleeding disorder; Variably decreased vWF:Ag Missense mutations and small in frame
(case reports) autosomal dominant and VIII:C. vWF activity deletions in vWF A1 repeat
decreased relative to antigen
despite presence of large and
intermediate multimers
Type 2N Uncommon: Variable bleeding disorder. Variable vWF:Ag and vWF Missense mutations within the N-
heterozygotes Homozygotes (or compound activity. Disporportionately terminus of mature vWF
may be heterozygotes) may resemble low VIII:C. Generally normal which interfere with FVIII binding
prevalent in autosomal haemophilia A. multimers. Decreased or
some Coinheritance may modify absent vWF binding to FVIII
populations severity of type 1
Reproduced from [4] with permission.
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been localized to an N-terminal 272 amino acid segment
and the primary binding domain for the platelet receptor
glycoprotein 1b has been mapped to the A1 repeat. The
primary collagen binding domain appears to lie within the
A3 domain whereas the RGDS sequence recognized by
integrins, such as the GpIIbIIIa platelet receptor, is near
the C-terminal end of the protein.
Molecular basis of vWD
Figure 3 illustrates the general molecular mechanisms that
should be considered when examining the molecular basis
of any genetic disease, including vWD. Perhaps the most
obvious way to inactivate a gene is by deletion of a
portion or all of the gene sequence itself. In the common
genetic disorder a-thalassaemia, gene deletions account
for the vast majority of patients. Although gene deletions
have been identi®ed in a small subset of type 3 vWD
patients, this appears to be a relatively rare mechanism for
vWD. As expected, vWD gene deletion is generally
associated with a quantitative de®ciency of vWF, though
a single inframe deletion removing all three A domains
has been reported in a patient with a type 2 variant [16].
A gene can also be inactivated by a single nucleotide
substitution or point mutation, or the insertion or deletion
of a few nucleotides within the DNA sequence. Mutations
of this type can result in the substitution of a single amino
acid (a missense mutation), an abrupt disruption of the
coding sequence of the gene by introduction of a new stop
codon (nonsense mutation), or a change in the reading
frame (frameshift mutation). Small mutations of this type
can also block the proper expression of the mRNA, either
by interfering with normal RNA processing or transcrip-
tion of the gene. Many of these mutations will result in
loss of vWF expression from the mutant allele due to
decreased or absent mRNA, or expression of an unstable
or non-functional protein. However, missense mutations
can also yield a stable vWF protein with a qualitative
abnormality. Indeed, missense mutations are the under-
lying molecular basis for most of the qualitative (type 2)
vWD variants.
Finally, it is important to keep in mind the possibility
that mutations in other genes outside of the vWF locus
itself may interfere with vWF function, leading to vWD.
This latter possibility can be addressed by performing
linkage analysis, as illustrated at the bottom of Fig. 3. The
latter approach uses polymorphism in or near the vWF
gene to trace the inheritance of the various vWF alleles
within a speci®c family. A strong correlation between a
speci®c vWF allele and vWD provides a clear indication
that the disease in that family is due to a mutation within
the vWF gene, even without knowing the precise nature of
the mutation itself. Alternatively, occurrence of the same
vWD phenotype in individuals in the same family who
have not inherited a common copy of the vWF gene would
strongly suggest a contribution from another gene.
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Fig. 2. The vWF gene, mRNA, and protein. The vWF gene and pseudogene are depicted at the top, with the boxes representing exons and solid
black lines introns. The vWF mRNA encodes the full prepro-vWF protein, as shown in the middle. The locations of signal peptide (sp) and
propeptide (Pro-)cleavage sites are indicated by arrowheads. The lettered boxes denote the series of repeated homologous segments. The
approximate localizations for known vWF functional domains within the mature vWF sequence are indicated at the bottom. Numbers beneath
the domains refer to amino acid residues within the mature vWF subunit. The general location of mutations associated with the most common
type 2 variants of vWD are depicted above the mRNA structure (adapted from [50] with permission).
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Though the contributions of other genes outside of the
vWF locus to vWD is a subject of intense interest for our
own research laboratory and others, it is important to
stress that all of the limited studies that have been
performed to date in classic vWD pedigrees have been
consistent with linkage to the vWF gene [17].
The ®rst genetic defect to be identi®ed in patients with
vWD were large gene deletions associated with type 3
vWD [18]. The advent of the polymerase chain reaction,
which made it possible to amplify and sequence small
amounts of vWF mRNA from peripheral blood platelets,
led to the identi®cation of the ®rst point mutations in the
vWF gene in two type 2 A vWD pedigrees [19]. Since that
time, a large number of mutations have been identi®ed,
accounting for most of the common qualitative (type 2)
variants of vWD and these ®ndings have had important
implications for our understanding of vWF structure and
function, as illustrated in Fig. 2. The known mutations
have been periodically reviewed and catalogued [4 20];
and an updated database is maintained on the World
Wide Web by an international consortium of scientists
(http://mmg2.im.med.umich.edu/vWF).
Type 2 A vWD
As illustrated in Fig. 2, the vast majority of type 2 A vWD
mutations are con®ned to the A2 domain. One of these
mutations, Arg834Trp, is particularly common, account-
ing for & 1/3 of type 2 A vWD patients. The
characteristic type 2 A vWD phenotype, loss of large
and intermediate size vWF multimers, can arise via two
distinct mechanisms [21], as illustrated in Fig. 4. In group
1 type 2 A vWD, the responsible mutation results in an
improperly folded protein that is retained in the
endoplasmic reticulum (ER) by the cell quality control
machinery. In a heterozygous patient who carries one
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Fig. 4. Alternative mechanisms for loss of large multimers in type 2 A
vWD. In group 1, mutant vWF subunits are retained within the ER
and only lower molecular weight homomultimers of normal subunits
are efficiently secreted. In group 2, heteromultimers of normal and
mutant subunits are secreted, but subsequently degraded to smaller
multimeric species by proteolysis in plasma. (Reproduced with
permission from [7].)
Fig. 3. Identification of DNA mutations responsible for genetic disease. Potential mechanisms responsible for genetic diseases such as vWD are
depicted here. At the top, a gene deletion removing part or all of the gene will result in an obvious disruption of gene function. Such deletions, or
more complex rearrangements of DNA, can often be detected by Southern blotting. Point mutations resulting in single nucleotide substitutions
or smaller insertions or deletions within the DNA sequence can disrupt the function of the gene in a variety of ways, as described in the text.
Finally, unknown mutations within the gene can be traced by linkage analysis, following the inheritance of a polymorphic DNA variation within
or near the gene in members of families with the disease. A strong correlation between the specific vWF allele and the disease suggest that a
mutation somewhere in the gene is responsible for the disorder. Alternatively, absence of such a correlation in a sufficiently large family would
indicate that the disease is due to a mutation in another gene located elsewhere within the genome.
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normal and one mutant copy of the gene, the larger vWF
multimers, would be more likely to contain one or more
mutant subunit. As a result, the largest multimers are
retained in the ER and only the smallest multimers,
presumably containing only the normal subunits, are
secreted from the cell, accounting for the characteristic
plasma vWF multimer pattern. This mechanism also
accounts for the dominant inheritance of type 2 A vWD.
In group 2, an entirely dierent mechanism is
responsible for the dominant loss of large vWF multimers.
Group 2 type 2 A vWF is normally secreted from the cell.
However, the mutant subunits have an increased suscept-
ibility to cleavage by a speci®c metalloproteinase present
in plasma. This protease cleaves normal vWF between
Tyr842 and Met843 [22]. Alterations in this process
appear to account for the unusually large vWF multimers
present in the plasma of patients with TTP [23, 24].
Group 2 type 2 A vWF is cleaved more readily by this
protease resulting in loss of the largest multimers, again
most likely to contain multiple mutant subunits. The
resulting plasma vWF multimer pattern also shows loss of
the largest and intermediate size multimers characteristic
of type 2 A vWD, but by this second mechanism.
Why some mutations result in group 1 and others in
group 2 type 2 A vWD is unknown. We hypothesize that
both mechanisms may result from disturbance of the same
speci®c structural motif within the A2 domain. When this
structure is severely disrupted, the misfolded protein is
recognized and retained within the ER. More subtle
alterations may escape the cell quality control machinery
but then render the protein more susceptible to proteo-
lysis. Consistent with this hypothesis, similar amino acid
substitutions can cause either group 1 or group 2 type 2 A
vWD. For example, substitution of Glu at Gly742 results
in group 2 type 2 A vWD whereas substitution of Arg at
the same position causes a group 1 phenotype.
Type 2 B vWD
The molecular mechanism responsible for type 2 B vWD
is distinct from that of type 2 A, though the phenotype is
again characterized by loss of large vWF multimers. In
type 2 B vWD, the mutation, generally resulting in a single
amino acid substitution, leads to increased anity of vWF
for its platelet receptor, GPIb, often associated with
spontaneous binding. The resulting vWF platelet com-
plexes are cleared rapidly from plasma, usually resulting
in mild thrombocytopenia as well as loss of the largest,
most haemostatically active vWF multimers. As shown in
Fig. 2, the vast majority of type 2 B vWD mutations are
con®ned to the A1 repeat, helping to de®ne the GPIb
binding domain within vWF. Indeed, four speci®c
mutations within a 35 amino acid segment of the A1
domain account for& 90% of type 2 B vWD [25, 26]. The
insights gained from molecular studies have led to the
reclassi®cation of type 1 MalmoÈ and type 1 New York as
type 2 B variants. These two disorders have been shown to
be due to the same mutation in the vWF A1 domain [27].
Though quite similar to other type 2 B mutations, the
resulting alteration of vWF function is more subtle and
the vWF plasma multimers may appear normal, hence the
earlier misclassi®cation as a type 1 variant.
Type 2N
As summarized in Table 1, the type 2 N variant is
associated with decreased vWF anity for FVIII, resulting
in disproportionately low FVIII levels in plasma [28]. This
phenotype results from the dependence of FVIII on
binding to vWF to ensure its stability in plasma. The
mutations responsible for type 2 N vWD are generally
con®ned to the N-terminal segment of vWF, helping to
further de®ne this critical functional domain within
the protein.
Our group was the ®rst to identify the Arg91 to Gln
mutation, the most common cause of type 2 N vWD [29].
Indeed, our ®ndings in the initial patient are instructive
for the issues that should be kept in mind when evaluating
missense mutations potentially associated with vWD.
This patient exhibited disproportionately reduced levels
of FVIII, most likely in conjunction with type 1 vWD
(though the mechanism for the latter defect has not yet
been characterized in this patient). The disproportionately
low FVIII levels led us to sequence the FVIII binding
domain by PCR ampli®cation of patient DNA. This
analysis identi®ed two mutations in this region, Arg91Gln
on one chromosome and Arg89Gln on the other! The
remarkable similarity between these two amino acid
substitutions initially left us puzzled as to whether one,
both, or neither was actually responsible for the decreased
FVIII binding. However, functional analysis of recombi-
nant protein carrying each of these mutations demon-
strated that the Arg89Gln mutation had no eect on FVIII
binding whereas binding was markedly decreased by the
Arg91Gln mutation. Consistent with this observation,
screening of a large number of normal individuals
demonstrated that the Arg89Gln mutation is a common
polymorphism in the general population whereas
Arg91Gln was only observed in the patient and none of
the control samples. This particular mutation is found in
over 50% of type 2 N patients and may be particularly
common in some populations [30]. This mutation, along
with most of the other reported type 2 N mutations, does
not result in complete disruption of FVIII binding and in
homozygous patients is associated with residual levels of
FVIII in the range of 5%. Thus, type 2 N vWD should be
in the dierential diagnosis for patients with mild or
moderate haemophilia A, but is generally not confused
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with severe haemophilia A. However, a recent report [31]
identi®ed a Glu24Lys mutation in a patient with & 1%
FVIII levels, raising the concern that this diagnosis should
also be considered in more severely aected patients.
Type 2 N vWD provides an instructive example of
locus heterogeneity; that is identical disease phenotypes
due to mutations in dierent genes. The distinction
between classic haemophilia A and type 2 N vWD is
evident from the dierent inheritance patterns (X-linked
recessive vs. autosomal recessive), though these diseases
may have very similar clinical presentations and labora-
tory values. Indeed, it is likely that some previous reports
of apparent haemophilia A in females or with an unusual
inheritance pattern, may have been due instead to type 2 N
vWD. These disorders can now be distinguished by a vWF
FVIII binding assay, which is available in specialized
clinical laboratories, particularly in Europe. As for the
type 2 A and 2 B variants discussed above, direct DNA
mutation detection has the potential to be of great clinical
value but is not yet routinely available.
Type 1 and Type 3 vWD
The quantitative variants of vWD, type 1 and type 3, are
clinically the most important. Type 3 is the most severe
form and accounts for the majority of patient that require
frequent or intensive medical care. Type 1 vWD, though
generally mild, is by far the most common, accounting for
* 70% of all cases of vWD. The prevalence of type 3
vWD has been estimated at & 1 : 1 000 000 [32±34],
though it may be higher in Scandinavia. A number of
mutations have been identi®ed in type 3 vWD patients
including rare gene deletions as discussed earlier. The
most common mutation is a deletion of a single nucleotide
in a run of 6 cytosines in exon 18, resulting in a frameshift.
This mutation was ®rst reported by BlombaÈ ck and
coworkers and has been identi®ed in a number of type 3
alleles in Scandinavia, including the original AÊ land Island
pedigree [35±37].
What is the relationship between type 1 vWD and type
3? The simplest explanation is that type 1 vWD represents
the heterozygous or carrier state for type 3 vWD. A
mutation that inactivate the vWF gene will result in
markedly reduced or absent vWF levels in the homo-
zygote, leading to type 3 vWD. In the heterozygote, the
presence of one inactivated and one normal allele should
lead to vWF levels that are approximately half normal,
resulting in mild bleeding. Though this may be the case in
some type 1 patients, there are several problems with this
simple explanation. First, in type 3 vWD, the inheritance
is frequently described as `recessive' with the obligate
carrier parents having no bleeding symptoms and often
entirely normal vWF levels. In addition, the prevalence of
type 1 vWD from epidemiological studies (as high as 1±
3% [38 39]); would be predicted to lead to a much higher
frequency of severe type 1 vWD than is observed.
The frequent lack of the manifestations of type 1 vWD
among type 3 carriers may be explained by incomplete
penetrance. Penetrance is the portion of individuals who
carry the causative genetic mutation that exhibit the
typical signs and symptoms of the disease. From
evaluation of large pedigrees with type 1 vWD [40], the
penetrance of the disease is estimate at & 60% of obligate
mutation carriers. It is likely that the penetrance of type 1
vWD is signi®cantly lower in unselected populations.
Taking this penetrance ®gure into account, the true
frequency of vWF gene mutation carriers could be
considerably higher than the 1±3% estimated prevalence
®gures cited above, and even more incompatible with the
observed frequency of type 3 vWD. These inconsistencies
may be explained in part by over-diagnosis of type 1 vWD
when based primarily on laboratory values, with some
`patients' perhaps simply representing the edge of the
normal distribution. Though it is also possible that some
cases of type 1 vWD may be due to mutations at another
genetic locus, as noted above, the limited linkage studies
that have been published to date are all consistent with
linkage to the vWF gene [17].
It is also possible that speci®c type 3 vWD alleles cause
symptoms in carriers, whereas other are silent. Our group
has noted an association of gene deletions and other
genetic defects leading to loss of vWF mRNA with
recessive inheritance in type 3 families. In contrast, such
alleles that are null at the mRNA level may be less
frequent in type 1 families [17, 41]. Perhaps mRNA null
mutations can be compensated for by increased produc-
tion of vWF from the normal allele. Alternatively, the
presence of an mRNA from the vWD allele may indicate a
corresponding mutant protein that interfere with the
expression of vWF from the normal allele. Eikenbloom
and coworkers [42] have demonstrated such a dominant
negative eect from mutation of a cysteine residue in the
D3 domain of vWD. However, expression studies of the
common exon 18 frameshift mutation failed to identify a
similar mechanism for this allele, even though it is
associated with both type 3 and type 1 vWD in the
original AÊ land pedigree [37].
Other genetic factors as modi®ers of plasma vWF
level
A number of genetic and environmental factors are likely
to contribute to the wide variability in clinical severity
among type 1 vWD patients. Environmental variables
such as thyroid hormone, oestrogen level, and stress are
all know to signi®cantly modify plasma vWF levels [17].
In addition, genetic studies suggest that & 60% of the
variation in plasma vWF levels is determined by genetic
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factors [43]. ABO blood group accounts for about 30% of
this genetic eect, with plasma vWF levels in type O
individuals 25±35% lower than in non-O individuals [44].
Thus, it appears likely that there are a number of other
genetic factors that could have a dramatic eect on
plasma vWF levels that, when taken together with ABO
and environmental eects, could account for the wide
variation in clinical severity and incomplete penetrance of
type 1 vWD. It is also possible that a subset of type 1 vWD
patients may have a combination of genetic modi®er
mutations without any defect at the vWF gene itself. This
hypothesis has important implications for the diagnosis
and treatment of vWD.
Our laboratory has recently employed the mouse as a
model system in which to study genetic modifying eects on
plasma vWF levels. We have been studying the RIIIS/J
inbred mouse strain ®rst identi®ed by Sweeney and cow-
orkers [45] as a model for type 1 vWD. When compared to
the common inbred strain C57BL6/J, RIIIS/J mice have
plasma vWF levels that are& 50%of normal, with a normal
multimer distribution. We initially showed that this altera-
tion was not related to a defect within the vWF gene [46] and
subsequently went on to identify the responsible gene as a
novel genetic locus on mouse chromosome 11 [47,48]. We
have recently succeeded in identifying the responsible
modi®er gene, which we have termed Mvwf for modi®er
of vWF, as a previously known genetic locus, Galgt2 [49].
GALGT2 is a glycosyltransferase enzyme which transfers
GalNac residues to a speci®c location on growing carbo-
hydrate structures of both N- and O-linked sugars. The
novel molecular mechanism we identi®ed as responsible for
the low vWF level in RIIIS/J may have important
implication, not only for vWF, but also for genetic
modi®cation for a number of other plasma proteins.
The mechanism responsible for the Mvwf phenotype is
illustrated in Fig. 5. Normally Galgt2 is expressed
primarily in the gut epithelial cell. The mutation in
RIIIS/J turns o expression of this gene in the gut and
instead turns it on in the entire vascular endothelial cell
bed, the site of plasma vWF synthesis. Thus, the mutation
in this disorder does not alter the GALGT2 protein
structure itself, but rather changes its expression pattern.
Expression of GALGT2 at the site of vWF synthesis
results in a unique sugar structure not normally present on
vWF. The altered vWF is rapidly cleared from plasma,
with a half life of & 10 min, compared to the normal
& 4±8 h of wild-type vWF. This results in a marked
decrease in plasma vWF levels, as much as 20-fold (to 5%)
when compared to certain wild mouse strains [49].
TheMvwfmolecular mechanism identi®ed in the RIIIS/J
mouse provides a potential explanation for a possible
subset of type 1 vWD unrelated to the vWF gene itself. It is
unlikely that this unique and unusual mutation mechanism
has also occurred independent in humans as a cause of
human type 1 vWD. However, the general paradigm of
altered protein processing determined by variation at other
genes could certainly apply to human vWD, as well as
diseases due to alterations in other plasma proteins.
Continued advances in understanding the complex deter-
minants of plasma vWF level should dramatically improve
our future ability to precisely diagnose and classify this
common human bleeding disorder.
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Fig. 5. Model for mechanism of Mvwf action. In most mouse strains, Galgt2 is expressed primarily in intestinal epithelial cells and Vwf is
expressed in vascular endothelial cells. vWF secreted from endothelial cells circulates in the plasma at normal steady-state levels. However, in
RIIIS/J mice, Galgt2 expression is switched from epithelial to endothelial cells, leading to the transfer of GalNAc (black pentagons) onto
oligosaccharides present on vWF. The novel sugar structure on the secreted vWF results in decreased steady-state plasma levels, either through
interference with the secretory pathway or more rapid clearance of vWF from plasma. (Reproduced with permission from [49].)
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